Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2016 Oct;31:73-81. doi: 10.1016/j.cytogfr.2016.07.005. Epub 2016 Aug 1.

The untold story of IFN-γ in cancer biology.

Author information

1
Department of Basic Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey.
2
Department of Basic Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey. Electronic address: gunes.esendagli@lycos.com.

Abstract

Interferon (IFN)-γ is the uppermost cytokine implicated in anti-tumor immunity. With its cytostatic, pro-apoptotic and immune-provoking effects, IFN-γ plays a central role in the recognition and elimination of transformed cells. Considering well-characterized anti-tumor effects of this cytokine, many clinical trials and immunotherapy approaches have been designed to reinforce IFN-γ-mediated immunity for different types of cancer. However, the outcomes were not satisfactory and leaded to questioning of alternative actions of IFN-γ. Many regulatory pathways can be induced by IFN-γ to protect the normal tissues from collateral damage and to facilitate the re-establishment of homeostasis. Nevertheless, malignant cells can take the advantage of IFN-γ as an inducer of mediators inhibiting anti-tumor immune reactions. In addition, under the influence of tumor-derived factors, certain types of immune cells are also licensed by IFN-γ to perform regulatory actions. This review focuses on the immune modulatory functions of IFN-γ in cancer as an alternative story to be told.

KEYWORDS:

Anti-tumor immunity; Cancer; Immune regulation; Immunotherapy; Interferon; Myeloid cell; T cell

PMID:
27502919
DOI:
10.1016/j.cytogfr.2016.07.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center